Clinical trials: Coronary Artery Disease Progression
Cardiovascular Disease, Coronary Artery Calcification
7 Year Follow-up Study of the DanRisk Population
OBJECTIVES: To investigate the incidence of cardiovascular events as well as progression of coronary artery calcium (CAC) in healthy middle-aged subjects over a period of 7 years, and the relation to traditional as well as new…
- Conditions
- Cardiovascular Disease, Coronary Artery Calcification, Atherosclerosis
- Trial name
- NCT02913144
- Volunteers
- 1,257 people
- Sponsor
- Odense University Hospital
Type 2 Diabetes, Coronary Artery Disease
Semaglutide Treatment On Coronary Progression
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis.
- Trial name
- STOP (NCT03985384)
- Testing
- Semaglutide 2 MG/1.5 ML Subcutaneous Solution
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Coronary Artery Disease, Hypertension
Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound
The purpose of this study is to evaluate the effect of intensive blood pressure control compared to standard blood pressure control on progression of coronary atherosclerosis by intravascular ultrasound in hypertensive patients…
- Trial name
- PREVUS (NCT01230216)
- Testing
- control systolic blood pressure less than 120 mmHg, control systolic blood pressure less than 140 mmHg
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Takeshi Morimoto
Obesity & Overweight, Coronary Heart Disease
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography…
- Trial name
- NCT07657676
- Testing
- Mazdutide
- Where
- China
- Volunteers
- 116 people
- Sponsor
- China National Center for Cardiovascular Diseases
Type 2 Diabetes, Coronary Artery Disease (CAD)
Evaluating Atherosclerotic Disease Progression in Patients With Diabetes Mellitus
People with type 2 diabetes have a much higher risk of heart disease. One common problem is when the blood vessels that supply the heart become narrowed or blocked by fatty deposits, called plaque.
- Conditions
- Type 2 Diabetes, Coronary Artery Disease (CAD), Atherosclerosis Cardiovascular Disease
- Trial name
- EVOLVE (NCT07237685)
- Where
- 2 sites in Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Chronic Heart Failure, Coronary Artery Disease
The Influence of Metformin on Chronic Heart Failure Clinical Course in Patients With Prediabetes
It is well known fact, that prediabetes is a predictor of high cardiovascular mortality, increasing the risk of developing such adverse cardiovascular events as myocardial infarction, stroke and sudden cardiac death.
- Conditions
- Chronic Heart Failure, Coronary Artery Disease, PreDiabetes
- Trial name
- NCT04549415
- Testing
- Metformin Hydrochloride, lifestyle modification
- Where
- Kyrgyzstan
- Volunteers
- 97 people
- Sponsor
- National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Coronary Heart Disease, Atherosclerosis
Fluvastatin AmelIorates aTHerosclerosis Study
The study is designed to assess the effect of statin on atherosclesrosis progression as well as to explore its potential mechanism besides lipid modifying , such as effect on inflammation and vascular calcification.
- Trial name
- FAITH (NCT01681199)
- Testing
- Fluvastatin extended release tablet
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Beijing Anzhen Hospital
Cardiovascular Diseases, Heart Diseases
Aortic Calcium: Epidemiology and Progression -- Ancillary to MESA
To study the epidemiology of aortic calcium.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Coronary Arteriosclerosis
- Trial name
- NCT00059124
- Volunteers
- 1,980 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Renal Transplant
Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
Primary objectives: A. To evaluate the effect of Zortress® versus standard immunosuppression therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and at 6, and 12 months in renal transplantation…
- Trial name
- NCT01612299
- Testing
- Zortress® /Everolimus
- Where
- United States
- Sponsor
- University of Kentucky
Paroxysmal Atrial Fibrillation, Coronary Artery Disease
The Assessment of Progression of Paroxysmal AF After CABG
The aim of this study is a comparative evaluation of progression of paroxysmal atrial fibrillation in patients with coronary artery disease after isolated CABG and CABG combined with pulmonary vein isolation.
- Trial name
- NCT02246803
- Testing
- CABG+Pulmonary vein isolation procedure, Isolated CABG
- Where
- Russia
- Volunteers
- 72 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Atherosclerosis
Progression of Early Subclinical Atherosclerosis
The overall objective of this study is to characterize the prevalence and progression rate of subclinical atherosclerotic lesions and to study their association to the imaging characteristics of atheroma plaques and to the…
- Trial name
- PESA (NCT01410318)
- Where
- Spain
- Volunteers
- 4,184 people, healthy volunteers welcome
- Sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Chronic Hepatitis C, Atherosclerosis
Hepatitis C Treatment and Atherosclerosis
This study will examine the effects of treatment for hepatitis C on atherosclerosis, or hardening of the arteries. Hepatitis C is a disease of the liver caused by a virus that can cause permanent damage to that organ.
- Trial name
- NCT00659256
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Atherosclerosis
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
- Trial name
- NCT00116831
- Testing
- Glipizide, rosiglitazone maleate
- Where
- 156 sites in United States, Argentina and 18 more
- Volunteers
- 672 people
- Sponsor
- GlaxoSmithKline
Atherosclerotic Disease, Plaque, Atherosclerotic
Natural History of Carotid Plaque as Determined by 3D Ultrasound
This proposed follow-up study aims to recruit participants from the original BioImage cohort for a one-time follow-up examination.
- Conditions
- Atherosclerotic Disease, Plaque, Atherosclerotic, Heart Diseases, Stroke
- Trial name
- BioImage2 (NCT03314818)
- Testing
- Ultrasound 3D Imaging
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Pieter Muntendam
Coronary Artery Disease
Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque
The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.
- Trial name
- Rosuzet-IVUS (NCT03169985)
- Testing
- Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day, Rosuvastatin 20 mg orally once a day
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Samsung Medical Center
Cardiovascular Diseases, Peripheral Vascular Diseases
Homocysteine and Progression of Atherosclerosis
In the first phase, to establish the relationship of progression of peripheral vascular disease (PVD) to plasma homocysteine. In the second phase, to conduct a randomized, controlled trial of folic acid treatment of plasma…
- Conditions
- Cardiovascular Diseases, Peripheral Vascular Diseases, Atherosclerosis, Cerebrovascular Disorders
- Trial name
- NCT00005338
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
CAD - Coronary Artery Disease
REWRITE-CAD Protocol: Risk Evaluation With AI-CPA to Reduce Progression and Improve Lifetime Care for Patients With Known Coronary Artery Disease
REWRITE-CAD is a prospective, randomized, multi-center trial assessing the management of asymptomatic participants with a history of PCI or MI who will undergo a blinded CCTA and be randomly assigned to either the test arm in…
- Trial name
- REWRITE-CAD (NCT07834372)
- Testing
- Heartflow Analysis
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- HeartFlow, Inc.
Coronary Artery Disease
The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification
Both Coronary Artery Calcification (CAC)and its annual progression are a strong predictors of cardiovascular events. The development of arterial calcification results from imbalance between calcification promoting and inhibiting…
- Trial name
- VitaK-CAC (NCT01002157)
- Testing
- Menaquinone-7 (Vitamin K2)
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Maastricht University Medical Center
Coronary Artery Disease, Coronary Artery Disease Progression
Critical Treatment of Coronary Artery Disease
Identifying the critical lesion of coronary artery disease and determining the interventional plan are significant for reducing adverse cardiovascular adverse events.
- Trial name
- CTCAD (NCT03195621)
- Testing
- Stent implantation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Southeast University, China
Coronary Heart Disease (CHD)
REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease
Intensive lipid-lowering therapy is a cornerstone treatment for coronary heart disease (CHD). However, coronary plaque progression persists in a subset of patients even under intensive lipid-lowering therapy, which may be…
- Trial name
- REALISTIC (NCT06936111)
- Testing
- Assessment of residual cholesterol and inflammatory risk factors
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Shanghai Zhongshan Hospital